Celltrion: Data support switching to Remicade biosimilar

Celltrion Inc. (KOSDAQ:068270) presented data from 10 real-world switching studies showing that biosimilar infliximab ( CT-P13) had "comparable efficacy and safety" to reference product Remicade infliximab from Johnson & Johnson (NYSE:JNJ) and Merck & Co. Inc. (NYSE:MRK) in patients with inflammatory bowel disease (IBD).

The data, presented at the European Crohn's and Colitis Organisation (ECCO) meeting in Amsterdam, were from almost 600 IBD patients in eight countries. Celltrion said the data "further support the appropriate switching of patients" to the biosimilar. ...